Positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery announced by Samsara Vision

News
Article

Results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively.

Samsara Vision publishes positive imtermediate-term visual and safety outcomes of SING IMT - Image credit: Adobe Stock / ©Photocreo Bednarek

(Image credit: Adobe Stock / ©Photocreo Bednarek)

Samsara Vision has reported intermediate-term visual and safety outcomes of the SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) in patients 6 months post-surgery. According to the company, SING IMT implantation improved distance and near vision, with a low impact on the corneal endothelium cell density and manageable safety outcomes.

Furthermore, results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively. The percentage of patients able to read at near distance increased from 28.6% at baseline to 97.1% at 6 months, with distance vision also being improved by ⁓3 lines at 6 months post-surgery.

The retrospective SING IMT study included 35 patients (55 years or older) with late-stage age-related macular degeneration (AMD). Starting 6 weeks after surgery, patients participated in a required rehabilitation program, attending 8 90-minute sessions every 2-to-3 weeks for 6 months to optimize their visual outcomes.

No clinically meaningful change from baseline was measured in intraocular pressure or anterior chamber depth. The mean (SD) change from baseline in corneal endothelial cell density at 6 months in operated eyes was -280.7 (315.9) cells/mm2 (-11.4 %).

"This 6-month review highlights the potential of SING IMT to restore meaningful vision to individuals blinded by AMD, while preserving long-term corneal health with its innovative design," said Prof. Toro, co-author of the study from University Hospital Federico II, Naples, Italy.

The SING MT is approved for use in CE Mark referenced countries, with 19 CE referenced countries having implanted the SING IMT in more than 400 patients.

References
Samsara Vision Announces Positive Six-Month Visual and Safety Outcomes from the SING IMT® (Smaller-Incision New-Generation Implantable Miniature Telescope). Press Release. Published January 13, 2025. Accessed January 13, 2025. https://www.businesswire.com/news/home/20250112004584/en/Samsara-Vision-Announces-Positive-Six-Month-Visual-and-Safety-Outcomes-from-the-SING-IMT%C2%AE-Smaller-Incision-New-Generation-Implantable-Miniature-Telescope

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
Dr. Mile Brujic discusses a case series on a novel gel for lacrimal occlusion.
Dr. Julie Rodman discusses retina, imaging, and posterior segment in SECO presentations
Dr. Julie Rodman previews her SECO presentations
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
© 2025 MJH Life Sciences

All rights reserved.